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1. Introduction
People with epilepsy (PWE) frequently suffer from comorbid
mood disorders. Lifetime prevalence ranges between 11% and
62% [1]. One of the major psychiatric comorbidities having a
negative impact on the quality of life in PWE is depression [2].
The relationship between depression and epilepsy may be
bidirectional; having depression would increase the risk of
epilepsy, and having epilepsy appears to increase the risk of
depression [3]. Suicide attempts among depressed PWE are
four- to ﬁvefold more frequent than in the general population
[4–6]. Depression has also been associated with higher rates of
drug resistance in PWE [7]. Considering these issues the
successful and safe treatment of depression associated with
epilepsy is of utmost clinical importance.
Also psychotherapy must be mentioned as effective and
safe therapeutic intervention in PWE suffering from depres-
sion [8].
Guidelines indicating the choice of psychotropic drugs in
PWE are mainly based on studies in patients without epilepsy,
as well as risk evaluation of seizures [9,10].
Antidepressants may impact the incidence of seizures
in a dose-related manner in line with the animal model of
epilepsy [11]. The anticonvulsive effect is noticed at low
doses and with the increase of the dose the effect is being
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a b s t r a c t
People with epilepsy (PWE) frequently suffer from comorbid mood and anxiety disorders.
Depression is one of the major psychiatric comorbidities having a negative impact on the
quality of life in people with epilepsy. A review of the literature indicates that themajority of
antidepressant-related seizures have been associated with either ultra-high doses or over-
dosing and, generally, the risk of antidepressant-associated seizures is low. Corresponding-
ly, there is some evidence indicating that antidepressants of most widely used groups may
additionally lower the risk of triggering seizures. Four antidepressants are not recom-
mended for patients with epilepsy, i.e.: amoxapine, bupropion, clomipramine and maproti-
line. Clinicians applying ﬁrst line of depression treatment in patients with epilepsy should
consider use of SSRIs or SNRIs, particularly sertraline, citalopram, mirtazapine, reboxetine,
paroxetine, ﬂuoxetine, escitalopram, ﬂuvoxamine, venlafaxine, duloxetine. Implementa-
tion of anticonvulsive drugs in depressed patients should include valproate, carbamazepine,
lamotrigine, gabapentin, pregabalin. The paper reviews the evidence for the clinical use of
antidepressants in PWE.
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reversed [12]. A review of the literature indicates that
most antidepressant-related seizures have been associat-
ed with either ultrahigh doses or particularly in over-
dosing [13].
The paper reviews best practice indications for antidepres-
sant treatment in patients with epilepsy.
2. Antidepressants – the impact on the
occurrence of seizures
People with epilepsy or with familial history of epilepsy, the
ones suffering fromother neurological disorders, patientswith
pre-treatment electroencephalographic (EEG) abnormalities,
cerebral arteriosclerosis, those suffering from other general
medical conditions like hypertensive encephalopathy and the
elderly ones are more likely to experience seizures related to
antidepressants [11].
First-generation antidepressants, particularly tricyclic anti-
depressants (TCAs) exhibit capacity to trigger seizures in
patients without epilepsy [14].
Amoxapine, bupropion, clomipramine and maprotiline
may trigger convulsions even if administered at the therapeu-
tic dose range [15]. Imipramine dosedup to 200 mgper daywas
associated with the increased seizure risk: from 0.1% to 0.6–
0.9% at higher doses [16].
Retrospective observational study has demonstrated that
selective serotonin reuptake inhibitors (SSRIs) or serotonin
and norepinephrin reuptake inhibitors (SNRIs) worsened
seizure frequency, but also may be associated with a possible
decrease in seizure frequency. This data revealed a drop-in
seizure frequency from ≥1 to below 1 seizure for month in
27.5% of patients with frequent seizures, non-relevant to
change in psychiatric symptoms, whatmay suggest that SSRIs
potentially yield a positive anticonvulsive effect in patients
with treatment-resistant epilepsy [17].
No inﬂuence of citalopram, mirtazapine and reboxetine on
the incidence of seizures was noticed in a 30-weeks study in
patients with temporal epilepsy and major depression [18].
Data from FDA Phases II and III clinical regulatory trials of
several TCAs, SSRIs, SNRI – venlafaxine, noradrenergic and
speciﬁc serotoninergic antidepressant (NaSSA) – mirtazapine,
and the norepinephrine–dopamine reuptake inhibitor (NDRI) –
bupropion in patients withmajor depression, indicate that the
incidence of seizures was signiﬁcantly lower among patients
assigned to antidepressants than to placebo [19]. Therefore,
the occurrence of a seizure in a depressed patient who is being
treated with an antidepressant drug may be the expression of
the natural course of psychiatric disorder and not of an
iatrogenic effect of the psychotropic drug [20].
3. ADT – mechanism of action and the
incidence of seizures
There are three main elements, which caused a creation of
psychopathology in epilepsy [21]: those related to the brain, as
in this case, factors with neurobiological characteristics
shared by depression and epilepsy [22], those related to
treatment, i.e. depressogenic anticonvulsants, such as tiaga-
bine, vigabatrin, topiramate, and phenobarbital [23] and those
unrelated to the brain, such as stigma and social discrimina-
tion or patients' use of maladaptive strategies (e.g., non-
acceptance of the disease) [24]. Kanner and Palac [25] agree
with this concept, stating that a combination of intrinsic and
extrinsic factors that act synergistically causes depression in
epilepsy.
Longer-term adaptations to antidepressants, mediated via
second-messenger systems and implicating changes in gene
expression and protein translation lead to downstream effects
on neurogenesis and other conditions of neuroplasticity, the
neuroendocrine system [peculiarly the hypothalamo–pitui-
tary–adrenal (HPA) axis], other neurotransmitter systems and
inﬂammatory pathways. Much evidence also denotes both
neurotrophins, (e.g. BDNF), and epigenetic mechanisms in
these manifold actions. These diverse pathways and mecha-
nisms become compelling when aiming to identify the
mechanisms by which these compounds may also impact
on epilepsy [26]. Astonishing hippocampal neuroplasticity is
considered to be a predominant feature of obtained epilepsy
and represents a strong candidate mechanism by which
antidepressant drugsmay impact on disease processes. While
HPA axis hyperactivity is one of the most stationary
characteristics in depressed patients [27], this system has
also been veriﬁed to be dysfunctional in epilepsy.
The ability of antidepressants to affect HPA axis regula-
tion and the evidence suggesting a damaging role of
glucocorticoids in epilepsy development, promotes the
HPA axis as a potential site of interaction whereby anti-
depressants could inﬂuence epileptogenesis and seizure
vulnerability. A broad literature circumscribes monoamine
anomalies in the pathophysiology of both epilepsy and
depression [28]. Since many of the new generation anti-
depressants pointmonoaminergic neurotransmission, these
systems present nominees to mediate the inﬂuence of
antidepressants on seizures and epilepsy evolution. Inﬂam-
mation is another biological process which is signiﬁcant in
the pathogenesis of epilepsy [29], which has also a connec-
tion with antidepressants [30].
4. Interaction between antidepressant drugs
and AEDs
Interactions and potential worsening of adverse events
resulting from the combination of antidepressant drugs and
antiepileptic drugs (AEDs) are important issue in everyday
clinical practice.
Clinicians should carefully look for two domains of
potential adverse effects: (1) increased weight gain that can
be caused by AEDs such as gabapentin, valproate, carbamaze-
pine, pregabalin, and the SSRIs and SNRIs, (2) sexual dysfunc-
tion: decreased libido, anorgasmia, and sexual impotence can
be relatively common with AEDs such as the barbiturates
(phenobarbital and primidone) but can also be seenwith other
enzyme-inducing AEDs, related to the synthesis of sex-
hormone-binding globulin, which binds the free fraction of
sex hormones, limiting their access to central nervous system
[20]. Antidepressants can also aggravate sexual dysfunction
[31].
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Some AEDs (e.g. carbamazepine) have been shown to
increase clearance of antidepressants, while some antide-
pressants can inhibit clearance of AEDs as they interact with
the cytochrome P450 hepatic enzyme system [79_TD$DIFF](Table 1) [32].
5. ADT in epilepsy
The adequate selection of AEDs for particular patients is the
key issue – prescribing drugs with negative psychotropic
characteristics to patients with a personal or family
psychiatric history must be avoided. Moreover, discontinu-
ation of AEDs which have mood-stabilizing properties (e.g.
lamotrigine, carbamazepine, valproate and oxcarbazepine)
or anxiolytic characteristics (e.g. gabapentin, benzodiaze-
pines or pregabalin) has to be monitored carefully since
these drugsmay be indicated with regard tomood disorders [80_TD$DIFF]
[15].
Some vital variables must be considered by the choice of
the speciﬁc SSRIs and/or SNRIs: (1) characteristics of depres-
sive episode (SNRIs are preferred for depressive episodes with
fatigue and psychomotoric decline; otherwise, SSRI should be
used); (2) therapeutic proﬁle in depressive and anxiety
disorders, given their high comorbidity in PWE; (3) possible
pharmacodynamic and pharmacokinetic interactions with
concomitant AEDs; and (4) potential adverse event proﬁle of
the speciﬁc SSRI drug that could worsen underlying medical
complications merged with the seizure disorder or other
attendant medical conditions. The implementation of the
therapeutic serum concentration of SSRIs and SNRIs may be
prevented by using ﬁrst generation AEDs such as phenytoin,
carbamazepine, phenobarbital, and primidone and the third
generation AED ruﬁnamide, which induce the cytochrome
P450 enzyme system [33–36].
One of the largest study included 97 patients with epilepsy
treated with sertraline. A possible, transient worsening of
seizures was observed in 5 patients and only one patient was
thought to suffer a clear deterioration in seizure control [37].
Two studies have even found an anticonvulsive effect of
citalopram and ﬂuoxetine in epilepsy [38,39]. SSRIs (e.g.,
citalopram, sertraline, ﬂuoxetine) and SNRIs (e.g., venlafaxine,
duloxetine) represent the ﬁrst-line agents for pharmacological
treatment [39–41]. On the other hand, tricyclic or tetracyclic
antidepressants and norepinephrine-dopamine reuptake
inhibitors (NDRI) should be avoided in the ﬁrst choice [40].
Noradrenergic and speciﬁc serotonergic antidepressants
(NaSSAs) appear to be safe in epilepsy as well [41]. Also
ketamine has recently been shown as promising antidepres-
sant [42], which actions may be linked to the mTOR pathway
[43], a pathway recently been implicated in an ample range of
models of epileptogenesis [44].
Table 1 – Antidepressants in PWE. Based on [18,19,50].
Drug Dosing Metabolism Interaction with ASDs Seizure risk Level of evidence
SSRIs Approved therapeutic
doses
Liver (CYP450) Carbamazepine, phenytoin (decrease
level of some SSRIs)
Low/no inﬂuence II
SNRIs Approved therapeutic
doses
Liver (CYP450) Carbamazepine (decreases level of
duloxetine)
Low/no inﬂuence II
Mirtazapine 15–45 mg Liver
(demethylation,
oxidation,
conjugation with
proteins)
Topiramate (increase sedation)
Carbamazepine, phenytoin (increase
metabolism)
Low/no inﬂuence IA
Reboxetine 4–12 mg Liver (CYP3A4) Phenytoin, carbamazepine,
phenobarbital (decrease level)
Low/no inﬂuence III
Imipramine 30–300 mg Liver (CYP1A2,
CYP3A4, CYP2C19,
CYP2D6)
Phenytoin, carbamazepine,
phenobarbital, topiramate, (decrease
level)
Medium (0.1–0.9%) III
Bupropion 150–300 mg Liver (mainly
CYP2B6)
Carbamazepine (increases metabolism)
Valproate (decreases metabolism)
Medium/high IA
Amoxapine 200–600 mg Liver (CYP450) Carbamazepine (increased metabolism)
Topiramate (increased sedation)
High II
Clomipramine 10–225 mg Liver (CYP3A4,
CYP2C19, CYP1A2)
Phenytoin, carbamazepine, topiramate
(decrease level)
High II
Maprotiline 25–150 mg Liver (CYP2D6,
CYP1A2)
Phenobarbital, topiramate (increase
sedation)
Carbamazepine (decrease level)
High III
[(Fig._1)TD$FIG]
Fig. 1 – Major depression treatment in epilepsy.
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5.1. ADT in temporal lobe epilepsy
Temporal lobe epilepsy (TLE) has a more signiﬁcant risk of
depression than extratemporal epilepsy. Patients with tempo-
ral lobe epilepsy commonly afﬂict major depression with a
prevalence rate between 20 and 60% [45–47]. Kühn et al [48]
investigated the efﬁcacy and safety of depression treatment
with mirtazapine, citalopram and reboxetine in patients with
temporal lobe epilepsy.
Cognitive-behavioral therapy (CBT) has a comparable effect
as SSRIs for treating MDD in patients with TLE. The main
malalignment of SSRIs was that, SSRIs appear to have less
inﬂuence on patients' quality of life (QOL), when equated to
CBT [81_TD$DIFF] 49].
6. Conclusion
In summary, indication for best practice for ADT in PWE is:
SSRIs or SNRIs including citalopram, escitalopram, sertra-
line, ﬂuoxetine, mirtazapine, reboxetine, paroxetine, ﬂuvox-
amine, venlafaxine and duloxetine. With the exception of
four drugs (amoxapine, bupropion, clomipramine and
maprotiline) antidepressant drugs are generally safe for
PWE when used at therapeutic doses [82_TD$DIFF](Fig. 1). The discerning
insight into this issue may lead to a supposition, that
antidepressant drug-induced convulsions are rather a result
of an overdose or slow metabolism which results in high
plasma concentrations of antidepressants [51]. Data appear
to reafﬁrm previous observations derived from open trials
that SSRIs and SNRIs do not aggravate seizure frequency and
therefore should be used for the treatment of comorbidmood
disorders in PWE [6,19–21].
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